Kanama21,Indwara ya epcoritamab ifite ibice bibiri bya T cell engager, yahawe uburenganzira bwo gusuzuma no gusuzuma imiti (CDE) y’ikigo cy’igihugu gishinzwe imiti y’ubuvuzi (NMPA). Iyi nyigo igenewe abarwayi bakuru bafite uburwayi bwa lymphoma ya follicular (FL) yasubiwemo cyangwa idashobora kugaragara, ikaba ari itsinda rikenewe cyane rya kanseri ya B cell.
Kugeza ubu, haracyari igeragezwa ryinshi ry’ikoranabuhanga rishya rirwanya kanseri mu Bushinwa rishaka abarwayi. Inama ku miti mishya n’ikoranabuhanga, ushobora kuvugana n’Ishami Mpuzamahanga ry’Ibitaro bya Oncology bya Beijing mu Karere k’Amajyepfo.
Nimero ya Terefone: 4008803716
Indangamuntu ya WeChat: 17801183037
Email：myimmnet@163.com
Ku bijyanye na Epcoritamab
Epcoritamab ni antibody ya IgG1-bispecific yakozwe hakoreshejwe ikoranabuhanga rya Genmab rya DuoBody kandi igatangwa mu buryo bworoshye. Ikoranabuhanga rya Genmab rya DuoBody-CD3 ryakozwe kugira ngo riyobore uturemangingo twa T dutoteza mu buryo bwihariye kugira ngo dutange igisubizo cy’ubudahangarwa bw’umubiri ku bwoko bw’uturemangingo twibasiwe. Epcoritamab yakozwe kugira ngo icyarimwe ifatanye na CD3 ku turemangingo twa T na CD20 ku turemangingo twa B kandi igatera kwica uturemangingo twa CD20+ binyuze mu turemangingo twa T.
Ku bijyanye na Follicular Lymphoma (FL)
Ubusanzwe FL ni ubwoko bwa lymphoma itari Hodgkin (NHL) ikura buhoro buhoro (cyangwa ikura buhoro buhoro) ikomoka kuri lymphocyte B kandi ni bwo bwoko bwa kabiri bwa NHL bukunze kugaragara cyane bugizwe na 20-30% by'abarwayi bose. Abantu bagera ku 15.000 barwara FL buri mwaka muri USii kandi ifatwa nk'aho idakira hakurikijwe uburyo busanzwe bwo kuvura.iii Abarwayi bakunze gusubira inyuma kandi, buri gihe iyo basubiye inyuma, gukira no gufata igihe cyo kwivuza gikurikiraho biba bigufi.iv Uko igihe kigenda gihita, guhinduka ku gukwirakwiza lymphoma nini ya B-cell (DLBCL), ubwoko bukomeye bwa NHL bujyana n'ingaruka mbi zo kubaho, bushobora kubaho ku barwayi barenga 25%.
EPCORE FL-1 (NCT05409066) ni igerageza ryakozwe mu cyiciro cya 3 rigamije gusuzuma umutekano n'ubushobozi bwa epcoritamab hamwe na rituximab na lenalidomide (R2) ugereranyije na R2 yonyine ku barwayi barembye/barwaye indwara ya follicular lymphoma (FL).
Ku itariki ya 7 Kanama,Genmab A/Syatangaje ibisubizo byiza by’igerageza rya EPCORE FL-1 ryakozwe mu cyiciro cya 3 risuzuma epcoritamab yo munsi y’umubiri, antibody y’umubiri, hamwe na rituximab na lenalidomide (R®2) ugereranyije na R2 yonyine mu kuvura abarwayi bakuru bafite lymphoma ya follicular (FL) yasubiwemo cyangwa idashobora kugaragara (R/R). Ubushakashatsi bwahuye n’ibipimo bibiri by’ibanze by’igipimo rusange cy’ubutabazi (ORR, agaciro ka p < 0.0001) n’ubuzima budafite iterambere (PFS, HR 0.21, agaciro ka p < 0.0001), bigaragaza itandukaniro rikomeye kandi rifite akamaro mu mibare mu bice byombi by’ubutabazi, bigabanya ibyago byo kwiyongera kw’indwara cyangwa urupfu ku kigero cya 79%.
Kugeza ubu, haracyari igeragezwa ryinshi ry’ikoranabuhanga rishya rirwanya kanseri mu Bushinwa rishaka abarwayi. Inama ku miti mishya n’ikoranabuhanga, ushobora kuvugana n’Ishami Mpuzamahanga ry’Ibitaro bya Oncology bya Beijing mu Karere k’Amajyepfo.
Nimero ya Terefone: 4008803716
Indangamuntu ya WeChat: 17801183037
Email：myimmnet@163.com
Igihe cyo kohereza: Nzeri-05-2025